Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

DoctorAdam vs Lumora

DoctorAdam
Graded #54

Higher grade

vs+9.800000000000011
Lumora
Graded #205

Lower grade

The verdict

DoctorAdam takes it — 75.9/100 to 66.1/100.

DoctorAdam grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. DoctorAdam is a Shopify-based telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral tablet forms, with flat all-in monthly pricing covering physician evaluation,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDoctorAdam +42
78
36
Dose & formulationDoctorAdam +13
88
75
Clinical oversightLumora +2
85
87
Labs & monitoringLumora +23
53
76
FulfillmentDoctorAdam +5
79
74
Contract termsEven
55
55
DoctorAdam · left barLumora · right bar

The numbers

MetricDoctorAdamLumora
WeighScore75.9/10066.1/100
GradeCC
Scorecard rank#54#205
Semaglutide$129/mo (starting dose, compounded)$199/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$229/mo (starting dose, compounded)$299/mo (starting dose, compounded)
Coverage44 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
DoctorAdam

Graded #54 · C

Strengths

  • Offers both injection and oral tablet forms of compounded semaglutide and tirzepatide
  • Flat all-in pricing — physician evaluation, medication, and free shipping included
  • Named pharmacy partners: Olympia Pharmaceuticals (Orlando, FL) and Carie Boyd Pharmaceuticals (Irving, TX)
  • LegitScript certified with 4.8/5 Trustpilot score from 5,400+ reviews and 100K+ patients
  • No hidden fees, no required recurring commitment, full refund if not prescribed

Where it loses points

  • Compounded medications are not FDA-approved individual drugs
  • No labs or dedicated coaching disclosed on public pages
  • Only 44 states served — AK, MA, MS, NJ, RI, and VT excluded despite homepage '50 states' claim
  • Dose-tier pricing not published; only starting prices visible without quiz
  • Shopify-based store rather than a dedicated health platform
Lumora

Graded #205 · C

Strengths

  • Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
  • Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
  • LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
  • Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
  • Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141

Where it loses points

  • Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
  • Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
  • Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
  • No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
  • Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard